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with newly diagnosed depressive disorder. The patients were followed up for one 
year after the index date (the first date of diagnosis). Psychotropic drugs used to 
treat depressive disorder included first- and/or second-generation antidepressant, 
benzodiazepine, sulpiride, and antipsychotics. The treatment duration and time to 
treatment by gender and age were evaluated by Cox regression model. Results: 
A total of 5,464 patients (men: 3,483, mean age: 36.1±9.9) with depressive disorder 
was identified. Median treatment duration was 123 days (men: 150 days, women 
92 days). 90.1% of patients was prescribed at least one psychotropic drug within 
30 days from the first date of diagnosis (84.5% in women and 93.1% in men). The 
proportion of patients who were prescribed at least one psychotropic drug for the 
first time after 6 months from the index date was 5.6% (men: 3.8%, women: 9.1%). 
The result showed that older patients were more likely to be treated longer period. 
In addition, men tend to be prescribed at least one psychotropic drug in a shorter 
period of time from the index date compared to that in women. ConClusions: 
This study suggested the trend of treatment disparity between men and women as 
well as age in working population with regard to treatment duration and time to 
prescription. Further study is needed for generalizability.
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objeCtives: PERFORM (Prospective Epidemiological Research on Functioning 
Outcomes Related to Major depressive disorder) is a 2-year prospective observa-
tional cohort study conducted in Europe (France, Germany, Spain, Sweden and UK). 
Objectives are to describe the functioning of patients with major depressive disorder 
(MDD) and factors associated with functional impairment. Here we compare charac-
teristics and outcomes of patients switching antidepressant treatment (ADT) with 
those initiating ADT at baseline, on an interim 1000-patient dataset. Methods: 
Outpatients were recruited from primary or secondary care. Inclusion criteria were: 
DSM-IV-TR diagnosis of MDD, age 18-65 years, initiation or first switch to an ADT, in 
monotherapy. In addition to socio-demographics and disease history, data collec-
tion included clinician assessments (MADRS and CGI-S) and patient-rated scales 
evaluating depression (PHQ-9), functioning (SDS), work productivity (WPAI-SHP) 
and quality of life (QoL - EQ-5D). Results: Of 947 analysable patients at inclusion, 
213 (23%) patients were switching (76% for lack of efficacy), versus 716 (77%) initi-
ating ADT. Switchers were slightly older (mean age 46 versus 43 years) and more 
often female (77% vs. 72% women). Switching patients had more severe symptom 
profiles: more had previous depressive episodes (34% vs. 24%) and previous suicide 
attempts (16% vs. 12%). Severity of current episode was greater for switchers (46% 
vs. 36% with a CGI-S score above “markedly ill”; 48% versus 38% with a PHQ-9 score 
above the severe depression threshold). MADRS scores were similar: 18.1 versus 
17.6. QoL was poorer for switchers (EQ-5D: 0.449 vs. 0.567), as was overall patient 
functioning (47% vs. 36% with an SDS total score in the highest quartile), while no 
difference was found for absenteeism (35% vs. 34%) and presenteeism (49% vs. 50%) 
(WPAI-SHP). ConClusions: Patients switching ADT had more severe symptom 
profiles, lower quality of life and higher functional impairment, compared to non-
switching patients.
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objeCtives: PERFORM (Prospective Epidemiological Research on Functioning 
Outcomes Related to Major depressive disorder) is a 2-year prospective observa-
tional cohort study conducted in Europe to describe the functioning of patients 
with major depressive disorder (MDD) and factors associated with functional 
impairment. Here we report the impact of patient-reported cognitive dysfunc-
tion (PRCD) on quality of life (QoL), work and overall functioning at baseline, on 
a preliminary 1000-patient dataset. Methods: Outpatients were recruited from 
primary or secondary care. Inclusion criteria were: DSM-IV-TR diagnosis of MDD, 
18-65 years old, initiation or first switch to an antidepressant, in monotherapy. 
Functioning was assessed by the SDS (Sheehan Disability Scale), work productiv-
ity by the WPAI-SHP (Work Productivity and Activity Impairment Questionnaire) 
and QoL by the EQ-5D (EuroQol-5 Dimensions) and SF-12 (12-Item Short-Form 
Health Survey). PRCD was assessed by the Perceived Deficit Questionnaire 5-item 
(PDQ-5). Descriptive analyses stratified on PDQ-5 quartiles were complemented 
with ANCOVA adjusted for severity of depression. Results: At inclusion, over 947 
analysable patients, mean PDQ-5 score (ranging from 0 to 20) was 11.5 (SD= 4.4). 
PRCD was associated with impairment of overall functioning, QoL and productiv-
ity. SDS total scores were 14.4, 18.5, 20.2, and 23.6 (first to fourth PDQ-5 quartiles, 
respectively) (p< 0.001). Similar patterns were observed for WPAI-SHP presentee-
ism scores (impairment while working: from 36.9% in first quartile to 64.4% in 
fourth quartile, p< 0.001; overall work impairment: from 41.5% to 71.3%, p< 0.001). 
These associations remained statistically significant after adjustment for baseline 
depression severity in multivariate analyses. A negative impact of PRCD was also 
observed on sick-leave length and on QoL. ConClusions: At inclusion, subjective 
cognitive dysfunction in depressed patients was associated with poorer function-
ing, work productivity and QoL. This is in addition to any negative impact of the 
to others antipsychotics in terms of PANSS total score and CGI-S score and a similar 
effect as compared to placebo on all metabolic outcomes. The probability to have 
a lower impact than aripiprazole on weight increase and fasting glucose level was 
respectively 75.5% and 65.9%. Probabilities to have a lower impact on cholesterol 
level and triglycerides compared to olanzapine, quetiapine or riperidone varied 
from 98% to 100%. ConClusions: Efficacy has been demonstrated for all reviewed 
treatments vs. placebo, with a similar effect. Lurasidone had a similar effect as 
compared to placebo and a less negative impact than olanzapine, quetiapine and 
risperidone on weight increase, triglycerides, total cholesterol level and than olan-
zapine on fasting glucose level.
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objeCtives: Vortioxetine (Lu AA21004) is an investigative multimodal antide-
pressant which demonstrated efficacy, safety and tolerability in Major Depressive 
Episode (MDE). The comparison of vortioxetine to marketed antidepressants guides 
decison makers and clinicians in their choice of treatment. The main study objective 
was to generate comparative evidence for the efficacy and acceptability of vortiox-
etine in MDE. Methods: Indirect comparisons were performed by meta-regression 
analysis, an extension of classical random-effect meta-analyses, to compare vorti-
oxetine to agomelatine, escitalopram, duloxetine, sertraline, venlafaxine IR/XR and 
vilazodone. To ensure comparability between studies, in terms of selection of patient 
population and exposure to treatment, only investigational drug and placebo arms 
from pre-registration placebo-controlled studies were included in the base case 
analyses. The main outcomes were efficacy, measured as the standardized mean dif-
ference between active treatment and placebo control in the change from baseline 
to 2 months of the primary endpoint (MADRS or HAM-D total score), and accept-
ability (the withdrawal rate due to adverse events) and expressed as the logarithm of 
the odds ratio (OR) between active treatment and placebo. Sensitivity analyses were 
performed with the inclusion of post-marketing authorization studies, adjustment 
for age/gender and on response and remission. Results: For efficacy, treatment 
effect estimates and p-values for vortioxetine versus comparators were: -0.16(0.11) 
versus agomelatine (negative effect favours vortioxetine); 0.09(0.42) versus dulox-
etine; -0.05(0.70) versus escitalopram; -0.04(0.83) versus sertraline; 0.12(0.33) versus 
venlafaxine IR/XR and -0.24(0.11) versus vilazodone. For acceptability, all but one OR 
(< 1) favoured vortioxetine: 1.77(0.03) versus agomelatine; 0.75(0.26) versus dulox-
etine; 0.67(0.28) versus escitalopram; 0.30(0.01) versus sertraline; 0.47(0.01) versus 
venlafaxine and 0.64(0.18) versus vilazodone. Meta-regression adjusted for age and 
gender demonstrated the robustness of the estimated differences between treat-
ments, as did sensitivity analyses including post-marketing trials. ConClusions: 
Vortioxetine is a promising intervention with efficacy comparable to marketed anti-
depressants in MDE and a favourable acceptability profile.
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objeCtives: The therapy of Attention Deficit/Hyperactivity Disorder (ADHD) with 
methylphenidate or atomoxetine, formerly only related to children and adolescents, 
is now extended to the adult population. Little is known about treatment patterns 
in Austria. The aim of this study was to evaluate the medication patterns of ADHD 
in 2012 in Austria, stratified by age and sex. Methods: The data analysis refers to 
the accounting data of the 13 major Austrian health insurance funds, covering more 
than 97% of the Austrian population. Provided in a pseudonymised manner, with 
availability of the individual patient parameters age and sex, all dispensed medica-
tion of methylphenidate or atomoxetine is included in the descriptive analysis. The 
prevalence of ADHD medication is evaluated regarding age and sex. Furthermore the 
prescribed daily dose in relation to the defined daily dose is pointed out. Results: 
A total of 9120 patients with ADHD medication in 2012 are included in the analy-
sis (22% female). One per cent of all patients with ADHD medication is in the age 
cohort of under 6 years, 47% are between 6 and 13, 22% are between 14 and 17, and 
30% are adults (18+). The relation between the defined daily dose (ddd) to the pre-
scribed daily dose (pdd) shows that 86% of children and adolescents have less than 
366 pdd in the whole year and only 1% has more than 732 pdd. 81% of the adults 
have less than 366 pdd and 6% have more than 732 pdd. ConClusions: While the 
variety of prescribed daily dose per patient is homogeneous during childhood and 
adolescence, this parameter spreads widely in adults. This could be an indicator of 
overuse or misuse. As the results reflect the prescription reality they can be used 
as a solid basis for further discussions, future evaluations and interventions about 
ADHD medication in Austria.
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objeCtives: Treatment disparity by gender and age among patients with depres-
sive disorder in working population has not been examined in Japan. This study 
examined treatment disparity by gender and age among patients newly diagnosed 
with depressive disorder based on the claims database of health insurance socie-
ties between 2008 and 2011 in Japan. Methods: Retrospective cohort database 
(N= 600,000) was followed up for four years to identify patients (18 ≤ age ≤ 65) 
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exclusion criteria. The combined odds ratio was 1.72 (95% CI: 1.432 to 2.070), indicating 
the odds of fetal malformation is higher among women taking antidepressants than 
those not receiving SSRIs. In the pairwise analysis, 2 of the 14 pairwise comparisons 
were statistically significant: fluoxetine compared to control (OR 1.774, 95% CI 1.008 
to 2.925); paroxetine compared to control (OR 1.752, 95% CI 1.057 to 2.953). The result-
ing pairwise odds ratios suggested a lowest odds of malformation to highest odds 
was citalopram, sertraline, paroxetine, fluoxetine. ConClusions: The risk of mal-
formation is an important consideration when treating pregnant women. This study 
suggests that there is an increase in the odds of fetal malformation when exposed 
to SSRIs in utero during the period of organogenesis. The risk appears to be highest 
with fluoxetine and paroxetine, and lower for citalopram.
MenTal HealTH – Cost studies
PMH18
BudgeT iMPaCT of PaliPeridone PalMiTaTe in ausTria
Ransmayr S.1, Mehnert A.2, Mahlich J.C.3
1University of Vienna, Vienna, Austria, 2Janssen Pharmaceutica NV, Beerse, Belgium, 3Janssen-
Pharmaceutical companies of Johnson & Johnson, Neuss, Germany
objeCtives: The costs of schizophrenia in Austria are high and new long acting 
injectable (LAI) antipsychotics might be able to reduce costs due to a reduction 
of hospital stays. We aim to estimate budget effects of the introduction of a new 
LAI (Paliperidone Palmitate) in Austria. Methods: A budget impact analysis was 
conducted that took direct costs of illness into account (i.e. costs for inpatient 
and outpatient services and drug costs). We used official Austrian remuneration 
prices as input parameters. The robustness of the model was checked by means 
of deterministic sensitivity analyses with regard to switch rates to Paliperidone 
Palmitate and rehospitalisation rates. Results: According to our calculations, 
direct total costs of schizophrenia in Austria reach € 254.36 million a year. The 
drug costs are € 26.14 million and the costs for inpatient and outpatient services 
are € 228.22 million. Within the next five years, drug costs will slightly decrease to 
€ 25.77 million due to a bigger market share of generic Quetiapine which offsets 
the higher drug costs of Paliperidon palmitate. The use of Quetiapine is associ-
ated with a higher rate of rehospitalisation. Therefore, costs for inpatient and 
outpatient services will increase to € 228.65 million, which results in an overall 
effect of € 60,000 additional costs compared to the situation without paliperidone 
palmitate. ConClusions: The introduction of a new treatment of schizophrenia 
in Austria is budget neutral.
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objeCtives: Depression is associated with reduced cognitive function and signifi-
cant health care costs; however, the extent to which these two are related remains 
unclear. This study compared follow-up health care costs for major depressive dis-
order patients with and without cognitive dysfunction after antidepressant (AD) 
initiation. Methods: A large US health plan affiliated with OptumInsight was used 
to identify depressed patients with a newly prescribed AD who could be surveyed 
to assess cognitive function. Patients with neurological diseases associated with 
cognitive dysfunction were excluded. Patients were mailed a survey invitation and 
consent form. Patients maintained eligibility by confirming a depressive diagno-
sis and no excluding diagnoses. Consenting, eligible patients were interviewed by 
telephone and completed 4 cognitive function tests. Patients were classified as 
“cognitive normal (CN)” or “cognitive dysfunction (CD)” based on test scores relative 
to normative data. All-cause health care costs in the 3 months post-AD initiation 
were calculated from pharmacy and medical claims. T-tests compared 3-month 
costs of CN versus CD. Gamma models with log link compared health care costs 
between CD and CN patients, adjusting for race, sex, age, education, employment, 
depression severity, and comorbidities. Results: A total of 13,537 patients were 
invited to participate in the study and 564 patients maintained eligibility and com-
pleted the study. Patients were mostly female (80%), mean age was 41 years, 98% 
had a high school degree or higher, and 84% were employed. A total of 45% (n= 255) 
met criteria for CD. Mean health care costs were $4,996 for all patients. Costs were 
$6,457 for the CD group compared to $3,787 for the CN (p = 0.038). In the gamma 
models with costs as the outcome, CD patients had costs 1.43 times higher than CN 
patients (95% CI: 1.13, 1.81). ConClusions: In this study population, health care 
costs were significantly higher in patients with cognitive dysfunction compared to 
those without cognitive dysfunction.
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objeCtives: To assess the economic burden and health care utilizations of 
patients diagnosed with post-traumatic stress disorder (PTSD) in the U.S. veteran 
population. Methods: Patients diagnosed with PTSD were identified (International 
Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis 
code 309.81) from the Veterans Health Administration (VHA) dataset from October 
01, 2009 through September 30, 2011. The first diagnosis date was designated as the 
index date. A comparator group was created by identifying patients without PTSD 
but with the same age, region, gender and index year, and who were matched by 
baseline Charlson Comorbidity Index. A randomly chosen index date served to 
severity of depression on these outcomes. These preliminary results need to be 
confirmed on the full dataset.
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objeCtives: To identify factors associated with early response at 4 weeks of treat-
ment with olanzapine and to assess whether early response is associated with 
better longer-term outcomes for patients with schizophrenia in China. Methods: 
A post-hoc analysis was conducted using data from the Chinese schizophrenia 
subgroup (n= 330) of a multicountry, 6-month, prospective, observational study of 
outpatients with schizophrenia/bipolar mania who were initiated or switched to oral 
olanzapine. Stepwise logistic regression controlling for baseline clinical character-
istics, participation in weight education program at baseline, and compliance with 
antipsychotics over first 4 weeks of olanzapine treatment was used to identify fac-
tors associated with early response. Mixed Models Repeated Measures with baseline 
covariates were used to compare outcomes over time between early responders and 
early non-responders to olanzapine. Results: A total of 130 patients (40%) achieved 
early response. The models revealed that significant factors associated with a higher 
likelihood of achieving early response were higher CGI-Sevirity score (OR= 1.51, 95% 
CI: 1.15-1.97), fewer years since first diagnosis (OR= 0.94, 95% CI: 0.90-0.98), a greater 
number of social interactions (OR= 1.22, 95% CI: 1.05-1.40), participation in a weight 
education program (OR= 1.81, 95% CI: 1.04-3.15) at study entry, and high medication 
compliance with antipsychotics during the first 4 weeks of treatment (OR= 2.98, 95% 
CI: 1.59-5.58). When compared to early non-responders, early responders achieved a 
significantly higher endpoint response and significantly greater symptom improve-
ment at end point (CGI-Severity) and a greater improvement in level of functional 
outcomes (all p< 0.05). ConClusions: High levels of compliance to prescribed 
antipsychotic and participation in a weight education program were associated with 
early response in schizophrenia patients in China. Early response was associated 
with greater improvement in symptomatic, functional and quality-of-life outcomes 
at 6 months compared to early non-response. Current findings are consistent with 
previous research outside of China.
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objeCtives: Patients with major depressive disorder (MDD) frequently suffer from 
concomitant pain symptoms, which are associated with higher depression sever-
ity and worse quality of life. We describe the baseline factors associated with pain 
persistence in patients with MDD during a 3-month follow-up period. Methods: 
Patients from Asia (n= 909) presenting with a new or first episode of MDD were 
enrolled in a 3-month prospective observational study. This report analyzes the 
709 (78%) patients assessed at baseline and 3 months. Demographics, depressive 
symptoms (Hamilton Depression Scale), overall severity (Clinical Global Impression 
Severity score), somatic symptoms (Somatic Symptom Inventory) and quality of 
life (Euro QOL -5D) were assessed. Logistic regression models were fitted to assess 
the relationship between baseline factors and pain persistence during follow-
up. Results: Of the 709 patients analyzed , 349 (49%) had pain at baseline. Forty 
three per cent of the patients (151) having pain at baseline still presented with pain 
at 3-months. Patients with persistent pain had more frequently suffered from previ-
ous MDD episodes (54% vs 39%) , were less likely to be older than 60 (11 vs. 21%), and 
had a higher number of medical comorbid conditions (14% vs 5% with two or more 
co-morbidities). The logistic model adjusting for other baseline covariates confirmed 
these results. ConClusions: A high proportion of patients with depression who 
presented with pain at baseline still suffered from pain symptoms at 3 months. A 
history of depression and the presence of other medical conditions were risk factors 
for pain persistence at 3-months.
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objeCtives: Assessing the safety of selective serotonin reuptake inhibitor (SSRI) 
use during pregnancy is complicated, especially given the array of treatment option. 
The objective of this study was to evaluate the risks of fetal malformation of SSRI 
use during pregnancy. Methods: A search for prospective studies evaluating fetal 
malformation with maternal use of citalopram, fluoxetine, paroxetine, or sertraline 
was conducted using the databases of MEDLINE, PsycINFO and EMBASE for the period 
of 1974 to March 21, 2013. The key terms used were: ‘serotonin reuptake inhibitors’, 
‘pregnancy’, ‘prospective studies’. The inclusion criteria in addition to prospective 
studies included: 1) malformation outcome; 2) citalopram, fluoxetine, paroxetine, 
and/or sertraline; 3) drug exposure in first trimester; and 4) compared to control 
group of either ‘no SSRI exposure’ or ‘nonteratogenic agents’. The exclusion criteria 
included: 1) evaluation of SSRI as a drug class, and 2) venlafaxine or bupropion. A 
Bayesian random-effects indirect treatment comparison model was used to perform 
the analysis. Results: The search resulted in 64 articles. Eight articles met inclusion/
